Pliant Therapeutics is a clinical-stage biopharmaceutical company developing treatments for fibrotic diseases with a focus on fibrotic tissue-specific inhibition of integrins and the TGF-β pathway.
February 24, 2022
Pliant Therapeutics is advancing drug development programs targeting a rangeclinical-stage ofbiopharmaceutical company developing treatments for fibrotic diseases, with a focus on fibrotic tissue-specific inhibition of integrins and the TGF-β pathway.
Reaching New Destinations
Pliant Therapeutics is a clinical-stage biopharmaceutical company leading the way in developing new treatments for fibrotic diseases. As fibrosis is a complex disease, few available treatments for fibrosis exist today. We are committed to advancing novel treatments and prepared to change the fibrosis treatment landscape.
Pliant is diving deep to understand the molecular drivers of fibrotic diseases to unlock potentially safer, and more effective therapies for patients.
Mission
Build the leading fibrosis company by combining world class expertise in fibrosis-biology, chemistry and technology to develop best-in-class,
tissue-specific, inhibitors of fibrotic diseases.
February 24, 2022
February 24, 2022